IP Library Granted Patent US 11,312,941
Granted Patent B2
US 11,312,941 · App. 16/434,726 · Granted Apr 26, 2022

Stem cell composition

Inventors: Silviu Itescu (Melbourne, AU); Paul Simmons (Melbourne, AU)
Assignee: MESOBLAST INTERNATIONAL SARL
C12N5/0663A61K35/28C12N2500/38C12N2501/39
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,312,941
App. No.
16/434,726
Granted
Apr 26, 2022
Kind
B2
Abstract

The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Claims (12)

1. A composition comprising a population of culture expanded, genetically unmodified mesenchymal precursor cells (MPCs), wherein the culture expanded cells express angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) at an Ang1:VEGF ratio between 2:1 and 30:1.

2. The composition of claim 1 , wherein said MPCs express Ang1:VEGF at a ratio between 5:1 and 20:1.

3. The composition of claim 1 , wherein said MPCs express Ang1 in an amount between 0.1 μg/10 6 cells and 1.0 μg/10 6 cells.

4. The composition of claim 1 , wherein said MPCs express Vascular Endothelial Growth Factor (VEGF) in an amount less than 0.05 μg/10 6 cells.

5. The composition of claim 1 , wherein said MPCs express VEGF in an amount less than 0.03 μg/10 6 cells.

6. A composition according to claim 1 , wherein the MPCs are produced by culture expanding a population of MPCs in vitro, wherein the culture expanding comprises: culturing a population of MPCs in a cell culture medium, which contains an L-ascorbic acid sodium salt; and/or

is supplemented with less than 10% v/v fetal calf serum (FCS); and/or

is supplemented with a non-fetal serum.

7. A composition according to claim 1 , wherein the cells are culture expanded in a culture medium which:

(a) comprises an L-ascorbic acid sodium salt; and/or

(b) is supplemented with less than 10% v/v fetal calf serum (FCS); and/or

(c) is supplemented with a non-fetal serum.

Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2019
From: ITESCU, SILVIU; SIMMONS, PAUL
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 049420/0740 →
Cited By (1)
US 12,616,722